bioequivalence
Sign in to savethumb|right|335px|A bioequivalency profile comparison of 150 mg extended-release bupropion as produced by [[Impax Laboratories for Teva and Biovail for GlaxoSmithKline]]
Article
11 sectionsContents
- Bioequivalence
- Regulatory definition
- The World Health Organization
- Australia
- Europe
- United States
- China
- Bioequivalence issues
- See also
- References
- External links
thumb|right|335px|A bioequivalency profile comparison of 150 mg extended-release bupropion as produced by [[Impax Laboratories for Teva and Biovail for GlaxoSmithKline]]
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.